• About
• Links
• Contact
• Sitemap

Sitemap > Breaking Research > Pain

• Pretreatment with antiserum against dynorphin, substance P, or cholecystokinin enhances the morphine-produced anti-allodynia in the sciatic nerve ligated mice.
• Terminating migraine with allodynia and ongoing central sensitization using parenteral administration of COX1/COX2 inhibitors.
• Almotriptan in migraine patients who respond poorly to oral sumatriptan: a double-blind, randomized trial.
• CRF2 receptor activation prevents colorectal distension induced visceral pain and spinal ERK1/2 phosphorylation in rats.
• Involvement of vagal opioid receptors in respiratory effects of morphine in anaesthetized rats.
• Effect of licofelone against mechanical hyperalgesia and cold allodynia in the rat model of incisional pain.
• The differential contribution of tumour necrosis factor to thermal and mechanical hyperalgesia during chronic inflammation.
• Analysis of structure-activity relationships for the 'B-region' of N-(4-t-butylbenzyl)-N'-[4-(methylsulfonylamino)benzyl]-thiourea analogues as TRPV1 antagonists.
• Chemical modification of the naphthoyl 3-position of JWH-015: in search of a fluorescent probe to the cannabinoid CB2 receptor.
• SAR and biological evaluation of novel trans-3,4-dimethyl-4-arylpiperidine derivatives as opioid antagonists.
• Induction of CX3CL1 expression in astrocytes and CX3CR1 in microglia in the spinal cord of a rat model of neuropathic pain.
• Epinephrine-induced excitation and sensitization of rat C-fiber nociceptors.
• Synthesis of long-chain amide analogs of the cannabinoid CB1 receptor antagonist N-(piperidinyl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716) with unique binding selectivities and pharmacological activities.
• Corticotropin-releasing factor receptor 1 mediates acute and delayed stress-induced visceral hyperalgesia in maternally separated Long-Evans rats.
• Herpes simplex virus type 1 latency-associated transcript expression protects trigeminal ganglion neurons from apoptosis.
• A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia.
• Influence of the dopamine D2 receptor knockout on pain-related behavior in the mouse.
• Efficacy of antiepileptic isomers of valproic acid and valpromide in a rat model of neuropathic pain.
• Involvement of an increased spinal TRPV1 sensitization through its up-regulation in mechanical allodynia of CCI rats.
• Analgesic effects of the selective group II (mGlu2/3) metabotropic glutamate receptor agonists LY379268 and LY389795 in persistent and inflammatory pain models after acute and repeated dosing.
• [Nalpha-benzylTyr1,cyclo(D-Asp5,Dap8)]- dynorphin A-(1-11)NH2 cyclized in the "address" domain is a novel kappa-opioid receptor antagonist.
• Adamantyl cannabinoids: a novel class of cannabinergic ligands.
• ATP is a mediator of chemosensory transduction in the central nervous system.
• Synthesis of novel 4-substituted-7-trifluoromethylquinoline derivatives with nitric oxide releasing properties and their evaluation as analgesic and anti-inflammatory agents.
• Analysis of structure-activity relationships for the 'A-region' of N-(4-t-butylbenzyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea analogues as TRPV1 antagonists.
• 1-Pentyl-3-phenylacetylindoles, a new class of cannabimimetic indoles.
• Differential behavioral tolerance to the delta-opioid agonist SNC80 ([(+)-4-[(alphaR)-alpha-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide) in Sprague-Dawley rats.
• The P2X3 antagonist P1, P5-di[inosine-5'] pentaphosphate binds to the desensitized state of the receptor in rat dorsal root ganglion neurons.
• Nociceptive effect of subcutaneously injected interleukin-12 is mediated by endothelin (ET) acting on ETB receptors in rats.
• Formulation, characterization, and evaluation of ketorolac tromethamine-loaded biodegradable microspheres.
• Anticonvulsant drugs for acute and chronic pain.
• Gabapentin for acute and chronic pain.
• Antidepressants for neuropathic pain.
• Endogenous opioid mechanisms partially mediate P2X3/P2X2/3-related antinociception in rat models of inflammatory and chemogenic pain but not neuropathic pain.
• Design, synthesis, and preliminary evaluation of gabapentin-pregabalin mutual prodrugs in relieving neuropathic pain.
• Ryanodine receptors are involved in muscarinic antinociception in mice.
• Characterization of a novel bivalent morphinan possessing kappa agonist and micro agonist/antagonist properties.
• Novel endomorphin-2 analogs with mu-opioid receptor antagonist activity.
• Intrarectal lidocaine is an effective treatment for abdominal pain associated with diarrhea-predominant irritable bowel syndrome.
• Calcium-acting drugs modulate expression and development of chronic tolerance to nicotine-induced antinociception in mice.
• Activation and activators of TRPV1 and their pharmaceutical implication.
• Focus on the three key enzymes hydrolysing endocannabinoids as new drug targets.
• Acetaminophen, aspirin, and caffeine versus sumatriptan succinate in the early treatment of migraine: results from the ASSET trial.
• Efficacy of the 5-HT1A agonist, buspirone hydrochloride, in migraineurs with anxiety: a randomized, prospective, parallel group, double-blind, placebo-controlled study.
• Anti-allodynic interactions between NMDA receptor channel blockers and morphine or clonidine in neuropathic rats.
• A prostacyclin receptor antagonist inhibits the sensitized release of substance P from rat sensory neurons.
• TRPA1 induced in sensory neurons contributes to cold hyperalgesia after inflammation and nerve injury.
• A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy. A preliminary report.
• Involvement of GABA and opioid peptide receptors in sevoflurane-induced antinociception in rat spinal cord.
• Selective inhibition of 2-AG hydrolysis enhances endocannabinoid signaling in hippocampus.
• Placebo effects mediated by endogenous opioid activity on mu-opioid receptors.
• CHF3381, a novel antinociceptive agent, attenuates capsaicin-induced pain in rats.
• Antinociceptive activity of the selective iNOS inhibitor AR-C102222 in rodent models of inflammatory, neuropathic and post-operative pain.
• Streptozotocin induced diabetes as a model of phrenic nerve neuropathy in rats.
• Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial.
• Identification of an achiral analogue of J-113397 as potent nociceptin/orphanin FQ receptor antagonist.
• Molecular modeling and 3D-QSAR studies of indolomorphinan derivatives as kappa opioid antagonists.
• Synthesis and evaluation of thiazole carboxamides as vanilloid receptor 1 (TRPV1) antagonists.
• In vitro photo-release of a TRPV1 agonist.
• Synthesis, molecular modelling and enzymatic evaluation of (+/-)3,5-diphenyl-2-thioxoimidazolidin-4-ones as new potential cyclooxygenase inhibitors.
• Identification and functional characterization of brainstem cannabinoid CB2 receptors.
• Synthesis of amide derivatives of [6-(3,5-dimethylpyrazol-1-yl)-3(2H)-pyridazinone-2-yl] acetic acid and their analgesic and anti-inflammatory properties.
• Synthesis and evaluation of analgesic/ anti-inflammatory and antimicrobial activities of 3-substituted- 1,2,4-triazole-5-thiones.
• A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone.
• Comparison of the effects of amitriptyline and flunarizine on weight gain and serum leptin, C peptide and insulin levels when used as migraine preventive treatment.
• Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine.
• 4-Phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives, a novel class of selective delta-opioid agonists.
• Efficacy of almotriptan 12.5 mg in achieving migraine-related composite endpoints: a double-blind, randomized, placebo-controlled study in patients controlled study in patients with previous poor response to sumatriptan 50 mg.
• The prolactin-releasing peptide antagonizes the opioid system through its receptor GPR10.
• Interaction between tramadol and two anti-emetics on nociception and gastrointestinal transit in mice.
• Spinal L-type calcium channel blockade abolishes opioid-induced sensory hypersensitivity and antinociceptive tolerance.
• Systemic administration of local anesthetics to relieve neuropathic pain: a systematic review and meta-analysis.
• A single dose of intrathecal morphine in rats induces long-lasting hyperalgesia: the protective effect of prior administration of ketamine.
• A role for endothelin in neuropathic pain after chronic constriction injury of the sciatic nerve.
• The effects of diacerhein on mechanical allodynia in inflammatory and neuropathic models of nociception in mice.
• Effect of diabetes on the mechanisms of intrathecal antinociception of sildenafil in rats.
• Comparison of morphine, ketorolac, and their combination for postoperative pain: results from a large, randomized, double-blind trial.
• Ephedrine blocks rat sciatic nerve in vivo and sodium channels in vitro.
• Does multimodal analgesia with acetaminophen, nonsteroidal antiinflammatory drugs, or selective cyclooxygenase-2 inhibitors and patient-controlled analgesia morphine offer advantages over morphine alone? Meta-analyses of randomized trials.
• Synthesis and structure-activity relationships of 8-azabicyclo[3.2.1]octane benzylamine NK1 antagonists.
• Structure-activity relationship study of 1,4-dihydropyridine derivatives blocking N-type calcium channels.
• New 1,3,4-thiadiazole derivatives endowed with analgesic and anti-inflammatory activities.
• 2-Aminothiophene-3-carboxylates and carboxamides as adenosine A1 receptor allosteric enhancers.
• Identification of a high-affinity binding site involved in the transport of endocannabinoids.
• Treatment of chronic visceral pain with brain stimulation.
• A role for cannabinoid receptors, but not endogenous opioids, in the antinociceptive activity of the CB2-selective agonist, GW405833.
• Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain.
• Visceral, inflammatory and neuropathic pain in glycine receptor alpha 3-deficient mice.
• Antinociception: mechanistic studies on the action of MD-354 and clonidine. Part 1. The 5-HT3 component.
• Synthesis and biological characterization of [3H] (2-amino-4,5,6,7-tetrahydrobenzo[b]thiophen-3-yl)-(4-chlorophenyl)-methanone, the first radiolabelled adenosine A1 allosteric enhancer.
• Expedited SAR study of high-affinity ligands to the alpha(2)delta subunit of voltage-gated calcium channels: Generation of a focused library using a solution-phase Sn2Ar coupling methodology.
• Synthesis and pharmacology of 11-nor-1-methoxy-9-hydroxyhexahydrocannabinols and 11-nor-1-deoxy-9-hydroxyhexahydrocannabinols: new selective ligands for the cannabinoid CB2 receptor.
• Risk of adverse gastrointestinal outcomes in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis.
• Tramadol/acetaminophen for the treatment of acute migraine pain: findings of a randomized, placebo-controlled trial.
• In vivo evaluation of (+)-MR200 as a new selective sigma ligand modulating MOP, DOP and KOP supraspinal analgesia.
• The analgesic efficacy of partial opioid agonists is increased in mice with targeted inactivation of the alpha2A-adrenoceptor gene.
• Analysis of human Nav1.8 expressed in SH-SY5Y neuroblastoma cells.
• The effect of site and type of nerve injury on the expression of brain-derived neurotrophic factor in the dorsal root ganglion and on neuropathic pain behavior.
• DSM-IV pain disorder in the general population. An exploration of the structure and threshold of medically unexplained pain symptoms.
• Kainate-induced excitation and sensitization of nociceptors in normal and inflamed rat glabrous skin.
• Pharmacological modulation of pain-related brain activity during normal and central sensitization states in humans.
• Actions of the FAAH inhibitor URB597 in neuropathic and inflammatory chronic pain models.
• Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists.
• Potent Dmt-Tic pharmacophoric delta- and mu-opioid receptor antagonists.
• Efficacy and tolerability of frovatriptan in acute migraine treatment: systematic review of randomized controlled trials.
• From pyrroles to pyrrolo[1,2-a]pyrazinones: a new class of mGluR1 antagonists.
• Synthesis and SAR of 1,2-trans-(1-hydroxy-3-phenylprop-1-yl)cyclopentane carboxamide derivatives, a new class of sodium channel blockers.
• Design, synthesis, and biological evaluation of substituted 3-alkylthio-4,5-diaryl-4H-1,2,4-triazoles as selective COX-2 inhibitors.
• Efficacy of mu-opioid agonists in the treatment of evoked neuropathic pain: Systematic review of randomized controlled trials.
• Recombinant human nerve growth factor with a marked activity in vitro and in vivo.
• Peripherally mediated antinociception of the mu-opioid receptor agonist 2-[(4,5alpha-epoxy-3-hydroxy-14beta-methoxy-17-methylmorphinan-6beta-yl)amino]acetic acid (HS-731) after subcutaneous and oral administration in rats with carrageenan-induced hindpaw inflammation.
• Topically administered ketamine reduces capsaicin-evoked mechanical hyperalgesia.
• The validity of the neuropathic pain scale for assessing diabetic neuropathic pain in a clinical trial.
• Involvement of adenosine A1 and A2A receptors in (-)-linalool-induced antinociception.
• Obesity and migraine: a population study.
• BDNF from microglia causes the shift in neuronal anion gradient underlying neuropathic pain.
• Deep tissue inflammation upregulates neuropeptides and evokes nociceptive behaviors which are modulated by a neuropeptide antagonist.
• Chronobiological characteristics of painful diabetic neuropathy and postherpetic neuralgia: diurnal pain variation and effects of analgesic therapy.
• Expression of opioid receptors and c-fos in CB1 knockout mice exposed to neuropathic pain.
• Activation of protein kinase B/Akt signaling pathway contributes to mechanical hypersensitivity induced by capsaicin.
• GW274150, a novel and highly selective inhibitor of the inducible isoform of nitric oxide synthase (iNOS), shows analgesic effects in rat models of inflammatory and neuropathic pain.
• Topiramate in the treatment of refractory chronic daily headache. An open trial.
• Nitric oxide and its modulators in chronic constriction injury-induced neuropathic pain in rats.
• An iontophoretic fentanyl patient-activated analgesic delivery system for postoperative pain: a double-blind, placebo-controlled trial.
• Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine.
• 5-Heteroatom-substituted pyrazoles as canine COX-2 inhibitors: Part 2. Structure-activity relationship studies of 5-alkylethers and 5-thioethers.
• Effectiveness of transdermal fentanyl patch for treatment of acute pain due to oral mucositis in patients receiving stem cell transplantation.
• Retinoic acid receptor beta2 promotes functional regeneration of sensory axons in the spinal cord.
• Painful diabetic neuropathy: a cross-sectional survey of health state impairment and treatment patterns.
• Treatment of intractable painful diabetic neuropathy with intravenous lignocaine.
• Vanilloid receptor (TRPV1)-deficient mice show increased susceptibility to dinitrobenzene sulfonic acid induced colitis.
• Sporadic onset of erythermalgia: a gain-of-function mutation in Nav1.7.
• Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.
• Synthesis and preliminary in vitro investigation of bivalent ligands containing homo- and heterodimeric pharmacophores at mu, delta, and kappa opioid receptors.
• Ketamine-induced potentiation of morphine analgesia in rat tail-flick test: role of opioid-, alpha2-adrenoceptors and ATP-sensitive potassium channels.
• Transient receptor potential vanilloid 1, calcitonin gene-related peptide, and substance P mediate nociception in acute pancreatitis.
• Novel evidence for hypersensitivity of visceral sensory neural circuitry in irritable bowel syndrome patients.
• A controlled crossover study of the selective serotonin reuptake inhibitor citalopram in irritable bowel syndrome.
• A meta-analysis of the placebo response in acute migraine and how this response may be influenced by some of the characteristics of clinical trials.
• Synthesis and CB1 receptor activities of dimethylheptyl derivatives of 2-arachidonoyl glycerol (2-AG) and 2-arachidonyl glyceryl ether (2-AGE).
• Phospholipase Cbeta1 modulates pain sensitivity, opioid antinociception and opioid tolerance formation.
• Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy.
• NSAID zaltoprofen possesses novel anti-nociceptive mechanism through blockage of B2-type bradykinin receptor in nerve endings.
• First "hybrid" ligands of vanilloid TRPV1 and cannabinoid CB2 receptors and non-polyunsaturated fatty acid-derived CB2-selective ligands.
• Cyclin-dependent kinase 5 activity regulates pain signaling.
• RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia.
• Zolmitriptan oral tablet in migraine treatment: high placebo responses in adolescents.
• Synthesis and analgesic activity of secondary amine analogues of pyridylmethylamine and positional isomeric analogues of ABT-594.
• 1-Phenyl-8-azabicyclo[3.2.1]octane ethers: a novel series of neurokinin (NK1) antagonists.
• An essential role for DeltaFosB in the nucleus accumbens in morphine action.
• Chronic pelvic pain treated with gabapentin and amitriptyline: a randomized controlled pilot study.
• Activation of cannabinoid CB1 receptors induces glucose intolerance in rats.
• Post-marketing experience with an opioid nasal spray for migraine: lessons for the future.
• Subcutaneous sumatriptan provides symptomatic relief at any pain intensity or time during the migraine attack.
• Systemic administration of minocycline inhibits formalin-induced inflammatory pain in rat.
• HSV-1-mediated NGF delivery delays nociceptive deficits in a genetic model of diabetic neuropathy.
• Age-related impact of neuropathic pain on animal behaviour.
• The additive antinociceptive interaction between WIN 55,212-2, a cannabinoid agonist, and ketorolac.
• The Runx1/AML1 transcription factor selectively regulates development and survival of TrkA nociceptive sensory neurons.
• A cross-sectional survey of health state impairment and treatment patterns in patients with postherpetic neuralgia.
• Polyamines are potent ligands for the capsaicin receptor TRPV1.
• Antinociceptive profile of salvinorin A, a structurally unique kappa opioid receptor agonist.
• Cannabinoid receptor type 2 agonists induce transcription of the mu-opioid receptor gene in Jurkat T cells.
• The analgesic activity of paracetamol is prevented by the blockade of cannabinoid CB1 receptors.
• Characterization of P-glycoprotein inhibition by major cannabinoids from marijuana.
• Intracellular targeting of truncated secretory peptides in the mammalian heart and brain.
• ACE inhibitor or angiotensin II receptor antagonist attenuates diabetic neuropathy in streptozotocin-induced diabetic rats.
• dextro- and levo-morphine attenuate opioid delta and kappa receptor agonist produced analgesia in mu-opioid receptor knockout mice.
• Synthesis and evaluation of NO-release from symmetrically substituted furoxans.
• Runx1 determines nociceptive sensory neuron phenotype and is required for thermal and neuropathic pain.
• Cannabinoid analgesia as a potential new therapeutic option in the treatment of chronic pain.
• Identification of a novel spiropiperidine opioid receptor-like 1 antagonist class by a focused library approach featuring 3D-pharmacophore similarity.
• Synthesis and activity of 1,3,5-triphenylimidazolidine-2,4-diones and 1,3,5-triphenyl-2-thioxoimidazolidin-4-ones: characterization of new CB1 cannabinoid receptor inverse agonists/antagonists.
• Cannabinoid CB2/CB1 selectivity. Receptor modeling and automated docking analysis.
• Pain in cancer. An outcome research project to evaluate the epidemiology, the quality and the effects of pain treatment in cancer patients.
• Pharmacological characterisation of the plant sesquiterpenes polygodial and drimanial as vanilloid receptor agonists.
• Antinociceptive effect and the mechanism of bee venom acupuncture (Apipuncture) on inflammatory pain in the rat model of collagen-induced arthritis: Mediation by alpha2-Adrenoceptors.
• Calcium channel alpha2-delta type 1 subunit is the major binding protein for pregabalin in neocortex, hippocampus, amygdala, and spinal cord: an ex vivo autoradiographic study in alpha2-delta type 1 genetically modified mice.
• Potent analgesic and anti-inflammatory activities of 1-furan-2-yl-3-pyridin-2-yl-propenone with gastric ulcer sparing effect.
• Reversal of neuropathic pain by alpha-hydroxyphenylamide: a novel sodium channel antagonist.
• A new class of bradykinin 1 receptor antagonists containing the piperidine acetic acid tetralin core.
• Synthesis and SAR of heteroaryl-phenyl-substituted pyrazole derivatives as highly selective and potent canine COX-2 inhibitors.
• Loss of TRPV1-expressing sensory neurons reduces spinal mu opioid receptors but paradoxically potentiates opioid analgesia.
• Disinhibition opens the gate to pathological pain signaling in superficial neurokinin 1 receptor-expressing neurons in rat spinal cord.
• Reduced pain sensitivity in mice lacking latexin, an inhibitor of metallocarboxypeptidases.
• The roles of different subtypes of opioid receptors in mediating the nucleus submedius opioid-evoked antiallodynia in a neuropathic pain model of rats.
• Effect of morphine on the release of excitatory amino acids in the rat hind instep: Pain is modulated by the interaction between the peripheral opioid and glutamate systems.
• Mechanisms of the antinociceptive action of gabapentin.
• mu- but not delta- and kappa-opioid receptors in the ventrolateral orbital cortex mediate opioid-induced antiallodynia in a rat neuropathic pain model.
• The COX-2 specific inhibitor Valdecoxib versus tramadol in acute ankle sprain: a multicenter randomized, controlled trial.
• Primary care physician perceptions of non-steroidal anti-inflammatory drug and aspirin-associated toxicity: results of a national survey.
• Analgesic efficacy of parenteral paracetamol (propacetamol) and diclofenac in post-operative orthopaedic pain.
• Association between daily pain and physical function among old-old adults living in the community: results from the ilSIRENTE study.
• Synergism between paracetamol and nonsteroidal anti-inflammatory drugs in experimental acute pain.
• Therapeutic efficacy of prosaposin-derived peptide on different models of allodynia.
• Structure-activity relationship of thiopyrimidines as mGluR5 antagonists.
• Opioid switching from oral slow release morphine to oral methadone may improve pain control in chronic non-malignant pain: a nine-month follow-up study.
• The role of COX-2 inhibitors in the perioperative setting: efficacy and safety--a systematic review.
• Involvement of TRP-like channels in the acute ischemic response of hippocampal CA1 neurons in brain slices.
• Identification of potent phenyl imidazoles as opioid receptor agonists.
• Does experimental pain response vary across the menstrual cycle? A methodological review.
• Neuropathic pain is enhanced in delta-opioid receptor knockout mice.
• Comparison of three models of neuropathic pain in mice using a new method to assess cold allodynia: the double plate technique.
• Celecoxib versus naproxen and diclofenac in osteoarthritis patients: SUCCESS-I Study.
• Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
• Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.
• Efficient synthesis of novel NK1 receptor antagonists: selective 1,4-addition of grignard reagents to 6-chloronicotinic acid derivatives.
• Functional characterization of opioid receptor ligands by aequorin luminescence-based calcium assay.
• Use of a prophylactic antiemetic with morphine in acute pain: randomised controlled trial.
• Inhibition of fatty acid amide hydrolase produces analgesia by multiple mechanisms.
• Adverse effects of gabapentin and lack of anti-allodynic efficacy of amitriptyline in the streptozotocin model of painful diabetic neuropathy.
• HSV-mediated expression of interleukin-4 in dorsal root ganglion neurons reduces neuropathic pain.
• 2-Fluoro-3-(4-nitro-phenyl)deschloroepibatidine is a novel potent competitive antagonist of human neuronal alpha4beta2 nAChRs.
• Reversal of morphine antinociceptive tolerance and dependence by the acute supraspinal inhibition of Ca(2+)/calmodulin-dependent protein kinase II.
• A high-capacity membrane potential FRET-based assay for NaV1.8 channels.
• Opioid-related side-effects after intrathecal morphine: a prospective, randomized, double-blind dose-response study.
• Efficacy of intrathecal adenosine for postoperative pain relief.
• Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis.
• Antinociceptive activities of alpha-truxillic acid and beta-truxinic acid derivatives.
• Safety and efficacy of the cyclooxygenase-2 inhibitors parecoxib and valdecoxib after noncardiac surgery.
• Opioid-induced hyperalgesia in a murine model of postoperative pain: role of nitric oxide generated from the inducible nitric oxide synthase.
• Opioid-induced hyperalgesia: a qualitative systematic review.
• Changes in pain behavior and histologic changes caused by application of tumor necrosis factor-alpha to the dorsal root ganglion in rats.
• Design and synthesis of novel hydrazide-linked bifunctional peptides as delta/mu opioid receptor agonists and CCK-1/CCK-2 receptor antagonists.
• N-substituted 4beta-methyl-5-(3-hydroxyphenyl)-7alpha-amidomorphans are potent, selective kappa opioid receptor antagonists.
• Pennsaid therapy for osteoarthritis of the knee: a systematic review and metaanalysis of randomized controlled trials.
• A randomized, double-masked, placebo-controlled pilot trial of extended IV lidocaine infusion for relief of ongoing neuropathic pain.
• Predictors of adherence to treatment in women with fibromyalgia.
• New insights into endocannabinoid degradation and its therapeutic potential.
• Dose-related antiallodynic effects of cyclic AMP response element-binding protein-antisense oligonucleotide in the spared nerve injury model of neuropathic pain.
• Role of 5-HT(1A) and 5-HT(2) receptors of dorsal and median raphe nucleus in tolerance to morphine analgesia in rats.
• BDNF in sensory neurons and chronic pain.
• VEGF 164 gene transfer by electroporation improves diabetic sensory neuropathy in mice.
• Ketamine for treatment of catheter related bladder discomfort: a prospective, randomized, placebo controlled and double blind study.
• Mirtazapine and its enantiomers differentially modulate acute thermal nociception in rats.
• SV2 is the protein receptor for botulinum neurotoxin A.
• Pharmacological evaluation of cannabinoid receptor ligands in a mouse model of anxiety: further evidence for an anxiolytic role for endogenous cannabinoid signaling.
• Targeting opioid receptor heterodimers: strategies for screening and drug development.
• Curcumin attenuates thermal hyperalgesia in a diabetic mouse model of neuropathic pain.
• Synthesis of some novel azo derivatives of 3,5-dimethyl-1-(2-hydroxyethyl)pyrazole as potent analgesic agents.
• Endogenous orphanin FQ/nociceptin is involved in the development of morphine tolerance.
• Anti-nociceptive effect of thalidomide on zymosan-induced experimental articular incapacitation.
• The kv4.2 potassium channel subunit is required for pain plasticity.
• Potent analgesic effects of a putative sodium channel blocker M58373 on formalin-induced and neuropathic pain in rats.
• Migraine: current therapeutic targets and future avenues.
• Non-steroidal antiinflammatory drugs and the risk of acute myocardial infarction.
• Racemic and chiral sulfoxides as potential prodrugs of the COX-2 inhibitors Vioxx and Arcoxia.
• Discovery, structure-activity relationship study, and oral analgesic efficacy of cyproheptadine derivatives possessing N-type calcium channel inhibitory activity.
• Prophylactic pharmacotherapy for migraine headaches.
• Potent modulation of the voltage-gated sodium channel Nav1.7 by OD1, a toxin from the scorpion Odonthobuthus doriae.
• Use of antiepileptics and tricyclic antidepressants in cancer patients with neuropathic pain.
• Decreasing pain and anxiety associated with patient-activated atrial shock: a placebo-controlled study of adjunctive sedation with oral triazolam.
• Haloperidol in the acute treatment of migraine: a randomized, double-blind, placebo-controlled study.
• Effect of acute and chronic administration of caffeine on pain-like behaviors in rats with partial sciatic nerve injury.
• Analgesic activity of a non-peptide imidazolidinedione somatostatin agonist: in vitro and in vivo studies in rat.
• A highly selective kappa-opioid receptor agonist with low addictive potential and dependence liability.
• Antinociceptive effects of tetrodotoxin (TTX) in rodents.
• TREK-1, a K+ channel involved in polymodal pain perception.
• Antiallodynic effect of etidronate, a bisphosphonate, in rats with adjuvant-induced arthritis: involvement of ATP-sensitive K+ channels.
• Signaling mechanisms of down-regulation of voltage-activated Ca2+ channels by transient receptor potential vanilloid type 1 stimulation with olvanil in primary sensory neurons.
• The symptom of pain with heart failure: a systematic review.
• Prophylactic gabapentin for prevention of postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy: A randomized, double-blind, placebo-controlled study.
• Antinociceptive efficacy of lacosamide in a rat model for painful diabetic neuropathy.
• Opioid receptor binding and antinociceptive activity of the analogues of endomorphin-2 and morphiceptin with phenylalanine mimics in the position 3 or 4.
• Cyclobutane derivatives as potent NK1 selective antagonists.
• Intrathecal treatment with sigma1 receptor antagonists reduces formalin-induced phosphorylation of NMDA receptor subunit 1 and the second phase of formalin test in mice.
• Opioid and cannabinoid receptors: friends with benefits or just close friends?
• Biology and therapy of fibromyalgia: pain in fibromyalgia syndrome.
• Structure-activity relationships of bifunctional peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors.
• Inhibition of paclitaxel-induced A-fiber hypersensitization by gabapentin.
• Pathophysiological mechanisms of neuropathic pain.
• Medications for neuropathic pain: current trends.
• Mu-delta opioid receptor functional interaction: Insight using receptor-G protein fusions.
• Treatment of chronic low back pain with successive injections of botulinum toxin a over 6 months: a prospective trial of 60 patients.
• Analgesic effects of the somatostatin sst4 receptor selective agonist J-2156 in acute and chronic pain models.
• CD4+ T-cell modulation of visceral nociception in mice.
• The role of neurokinin 1 receptors in the maintenance of visceral hyperalgesia induced by repeated stress in rats.
• The analgesic effects of perioperative gabapentin on postoperative pain: a meta-analysis.
• Relevance of tumour necrosis factor-alpha for the inflammatory and nociceptive responses evoked by carrageenan in the mouse paw.
• Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonist.
• Role of kappa- and delta-opioid receptors in the antinociceptive effect of oxytocin in formalin-induced pain response in mice.
• Synthesis and biological activity of nociceptin/orphanin FQ(1-13)NH2 analogues modified in 9 and/or 13 position.
• Morphine, oxycodone, methadone and its enantiomers in different models of nociception in the rat.
• Morphine-6-glucuronide: morphine's successor for postoperative pain relief?
• A rat model of bone cancer pain induced by intra-tibia inoculation of Walker 256 mammary gland carcinoma cells.
• Altered nociceptive response in ADAM11-deficient mice.
• Amino substituted analogs of 1-phenyl-3-phenylimino-2-indolones with potent galanin Gal3 receptor binding affinity and improved solubility.
• Poly(ADP-ribose) polymerase inhibition alleviates experimental diabetic sensory neuropathy.
• Hormonal and reproductive factors are associated with chronic low back pain and chronic upper extremity pain in women--the MORGEN study.
• A 2-week, multicenter, randomized, double-blind, placebo-controlled, dose-ranging, phase III trial comparing the efficacy of oxymorphone extended release and placebo in adults with pain associated with osteoarthritis of the hip or knee.
• High-throughput screening for the discovery of inhibitors of fatty acid amide hydrolase using a microsome-based fluorescent assay.
• Synaptic amplifier of inflammatory pain in the spinal dorsal horn.
• Atypical anxiolytic-like response to naloxone in benzodiazepine-resistant 129S2/SvHsd mice: role of opioid receptor subtypes.
• The pharmacology and regulation of T type calcium channels: new opportunities for unique therapeutics for cancer.
• N-Tetrahydroquinolinyl, N-quinolinyl and N-isoquinolinyl biaryl carboxamides as antagonists of TRPV1.
• Design and synthesis of new water-soluble tetrazolide derivatives of celecoxib and rofecoxib as selective cyclooxygenase-2 (COX-2) inhibitors.
• Selective COX-2 inhibitors. Part 1: synthesis and biological evaluation of phenylazobenzenesulfonamides.
• Differential role of 5-HT1A and 5-HT1B receptors on the antinociceptive and antidepressant effect of tramadol in mice.
• Pharmacological characterization of recombinant N-type calcium channel (Cav2.2) mediated calcium mobilization using FLIPR.
• Fluvoxamine, a selective serotonin reuptake inhibitor, exerts its antiallodynic effects on neuropathic pain in mice via 5-HT2A/2C receptors.
• Migraine and risk of cardiovascular disease in women.
• Gabapentin treatment of neurogenic overactive bladder.
• Lack of analgesic effect of parecoxib following laparoscopic cholecystectomy.
• Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain - relation to brain concentration.
• Raphe magnus neurons help protect reactions to visceral pain from interruption by cutaneous pain.
• Activation of Src-family kinases in spinal microglia contributes to mechanical hypersensitivity after nerve injury.
• Opioid requirement after arthroscopy is associated with decreasing glucose levels and increasing PGE2 levels in the synovial membrane.
• Design, synthesis, and biological evaluation of a new class of small molecule peptide mimetics targeting the melanocortin receptors.
• Design, synthesis, and biological evaluation of (E)-3-(4-methanesulfonylphenyl)-2-(aryl)acrylic acids as dual inhibitors of cyclooxygenases and lipoxygenases.
• Nitric oxide deficiency promotes vascular side effects of cyclooxygenase inhibitors.
• Enhancement of morphine analgesic effect with induction of mu-opioid receptor endocytosis in rats.
• Activation of alpha2-adrenoceptors in the trigeminal region produces sex-specific modulation of nociception in the rat.
• Epibatidine isomers and analogues: structure-activity relationships.
• Validation of a novel point-of-care nerve conduction device for the detection of diabetic sensorimotor polyneuropathy.
• A placebo-controlled study of memantine for the treatment of human immunodeficiency virus-associated sensory neuropathy.
• Prostaglandin E2 receptor EP4 contributes to inflammatory pain hypersensitivity.
• Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial.
• Cardiovascular risk and inhibition of cyclooxygenase: a systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2.
• Adverse effects of cyclooxygenase 2 inhibitors on renal and arrhythmia events: meta-analysis of randomized trials.
• TRPV1 receptors in the CNS play a key role in broad-spectrum analgesia of TRPV1 antagonists.
• Prostacyclin antagonism reduces pain and inflammation in rodent models of hyperalgesia and chronic arthritis.
• Carbamazepine interacts with a slow inactivation state of NaV1.8-like sodium channels.
• Gabapentin enhances the analgesic response to morphine in acute model of pain in male rats.
• Nonsteroidal antiinflammatory drugs and acute myocardial infarction in patients with no major risk factors.
• Extent of renal effect of cyclo-oxygenase-2-selective inhibitors is pharmacokinetic dependent.
• Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic anti-inflammatory drugs? Arguments in favor.
• Does a coxib-associated thrombotic risk limit the clinical use of the compounds as analgesic, antiinflammatory drugs? Arguments against.
• Selective COX-2 inhibitors and risk of thromboembolic events - regulatory aspects.
• Design, synthesis, and biological evaluation of new 1,8-naphthyridin-4(1H)-on-3-carboxamide and quinolin-4(1H)-on-3-carboxamide derivatives as CB2 selective agonists.
• Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction.
• Pain hypersensitivity in rats with experimental autoimmune neuritis, an animal model of human inflammatory demyelinating neuropathy.
• Use-dependent block by lidocaine but not amitriptyline is more pronounced in tetrodotoxin (TTX)-Resistant Nav1.8 than in TTX-sensitive Na+ channels.
• Allodynia and hyperalgesia suppression by a novel analgesic in experimental neuropathic pain.
• Therapeutic levels of aspirin and salicylate directly inhibit a model of angiogenesis through a Cox-independent mechanism.
• Efficacy of duloxetine in painful symptoms: an analgesic or antidepressant effect?
• Duloxetine for patients with diabetic peripheral neuropathic pain: a 6-month open-label safety study.
• Cobrotoxin-containing analgesic compound to treat chronic moderate to severe cancer pain: results from a randomized, double-blind, cross-over study and from an open-label study.
• Pain sensitivity is altered in animals after subchronic ketamine treatment.
• N-type calcium channel blockers: novel therapeutics for the treatment of pain.
• Design and characterization of a noncompetitive antagonist of the transient receptor potential vanilloid subunit 1 channel with in vivo analgesic and anti-inflammatory activity.
• Establishment of a rodent model of HIV-associated sensory neuropathy.
• Nicotinamide reverses neurological and neurovascular deficits in streptozotocin diabetic rats.
• 30-day mortality after peptic ulcer perforation among users of newer selective COX-2 inhibitors and traditional NSAIDs: a population-based study.
• Identification of novel, orally bioavailable spirohydantoin CGRP receptor antagonists.
• Arylsulfonamides as a new class of cannabinoid CB1 receptor ligands: identification of a lead and initial SAR studies.
• Antidepressants enhance the antinociceptive effects of carbamazepine in the acetic acid-induced writhing test in mice.
• Pharmacological profiles of the novel analgesic M58996 in rat models of persistent and neuropathic pain.
• Comparison of gene expression profiles in neuropathic and inflammatory pain.
• Halogenation of 4-hydroxy-3-methoxybenzyl thiourea TRPV1 agonists showed enhanced antagonism to capsaicin.
• Novel T-type calcium channel blockers: dioxoquinazoline carboxamide derivatives.
• Discovery of diphenyl amine based sodium channel blockers, effective against hNav1.2.
• Beneficial action of 2,4,4-trimethyl-3-(15-hydroxypentadecyl)-2-cyclohexen-1-one, a novel long-chain fatty alcohol, on diabetic hypoalgesia and neuropathic hyperalgesia.
• Reduction of anion reversal potential subverts the inhibitory control of firing rate in spinal lamina I neurons: towards a biophysical basis for neuropathic pain.
• Effects of trolox on nerve dysfunction, thermal hyperalgesia and oxidative stress in experimental diabetic neuropathy.
• A role for adrenomedullin as a pain-related peptide in the rat.
• Antinociceptive effect of cannabinoid agonist WIN 55,212-2 in rats with a spinal cord injury.
• Analgesic effects of serotonergic, noradrenergic or dual reuptake inhibitors in the carrageenan test in rats: evidence for synergism between serotonergic and noradrenergic reuptake inhibition.
• Antinociceptive effect of antisense oligonucleotides against the vanilloid receptor VR1/TRPV1.
• Structure-activity relationships of the ultrapotent vanilloid resiniferatoxin (RTX): the homovanillyl moiety.
• Antinociceptive effect of methyleugenol on formalin-induced hyperalgesia in mice.
• Inflammation-induced reduction of spontaneous activity by adjuvant: A novel model to study the effect of analgesics in rats.
• Nerve injury induces robust allodynia and ectopic discharges in Nav1.3 null mutant mice.
• Antinociception mediated by alpha(2)-adrenergic activation involves increasing tumor necrosis factor alpha (TNFalpha) expression and restoring TNFalpha and alpha(2)-adrenergic inhibition of norepinephrine release.
• GW406381, a novel COX-2 inhibitor, attenuates spontaneous ectopic discharge in sural nerves of rats following chronic constriction injury.
• Possible involvement of opioidergic systems in the antinociceptive effect of the selective serotonin reuptake inhibitors in sciatic nerve-injured mice.
• An estrogen receptor-beta agonist is active in models of inflammatory and chemical-induced pain.
• Periaqueductal gray knockdown of V2, not V1a and V1b receptor influences nociception in the rat. yj6676@yahoo.com.
• GTP cyclohydrolase and tetrahydrobiopterin regulate pain sensitivity and persistence.
• Pain control by CXCR2 ligands through Ca2+-regulated release of opioid peptides from polymorphonuclear cells.
• A randomized controlled trial of duloxetine in diabetic peripheral neuropathic pain.
• Cyclic MrIA: a stable and potent cyclic conotoxin with a novel topological fold that targets the norepinephrine transporter.
• Synthesis and biological evaluation of novel T-type calcium channel blockers.
• Structure-activity relationships of novel non-competitive mGluR1 antagonists: a potential treatment for chronic pain.
• Synthesis and biological evaluation of methanesulfonamide analogues of rofecoxib: Replacement of methanesulfonyl by methanesulfonamido decreases cyclooxygenase-2 selectivity.
• Roles of voltage-dependent sodium channels in neuronal development, pain, and neurodegeneration.
• Impaired function and expression of P-glycoprotein in blood-brain barrier of streptozotocin-induced diabetic rats.
• Interactions between NTS2 neurotensin and opioid receptors on two nociceptive responses assessed on the hot plate test in mice.
• 3D pharmacophore based virtual screening of T-type calcium channel blockers.
• Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
• Mice deficient for galanin receptor 2 have decreased neurite outgrowth from adult sensory neurons and impaired pain-like behaviour.
• muO-conotoxin MrVIB selectively blocks Nav1.8 sensory neuron specific sodium channels and chronic pain behavior without motor deficits.
• Analgesic agents without gastric damage: design and synthesis of structurally simple benzenesulfonanilide-type cyclooxygenase-1-selective inhibitors.
• Abnormal function of C-fibers in patients with diabetic neuropathy.
• Microglia: a cellular vehicle for CNS gene therapy.
• Low-dose naltreoxone for the treatment of irritable bowel syndrome: a pilot study.
• Improving the loading and release of NSAIDs from pHEMA hydrogels by copolymerization with functionalized monomers.
• Activation of transcription factor c-jun in dorsal root ganglia induces VIP and NPY upregulation and contributes to the pathogenesis of neuropathic pain.
• Involvement of mGluR5 in the ethanol-induced neuropathic pain-like state in the rat.
• A high throughput fluorescent assay for measuring the activity of fatty acid amide hydrolase.
• The discovery of 6-[2-(5-chloro-2-{[(2,4-difluorophenyl)methyl]oxy}phenyl)-1-cyclopenten-1-yl]-2-pyridinecarboxylic acid, GW848687X, a potent and selective prostaglandin EP1 receptor antagonist for the treatment of inflammatory pain.
• Chemotherapy-evoked painful peripheral neuropathy: analgesic effects of gabapentin and effects on expression of the alpha-2-delta type-1 calcium channel subunit.
• Behavioral and pharmacological description of oxaliplatin-induced painful neuropathy in rat.
• Vinpocetine and piracetam exert antinociceptive effect in visceral pain model in mice.
• Management of common opioid-induced adverse effects.
• Identification of the alpha2-delta-1 subunit of voltage-dependent calcium channels as a molecular target for pain mediating the analgesic actions of pregabalin.
• Design, synthesis, and biological evaluation of 1,3-dioxoisoindoline-5-carboxamide derivatives as T-type calcium channel blockers.
• Transdermal delivery of nonsteroidal anti-inflammatory drugs mediated by polyamidoamine (PAMAM) dendrimers.
• Inhibition of neuronal nitric oxide synthase antagonizes morphine antinociceptive tolerance by decreasing activation of p38 MAPK in the spinal microglia.
• Intrathecal administration of the common carboxyl-terminal decapeptide in endokinin A and endokinin B evokes scratching behavior and thermal hyperalgesia in the rat.
• Molecular mechanism for analgesia involving specific antagonism of alpha9alpha10 nicotinic acetylcholine receptors.
• Human Opiorphin, a natural antinociceptive modulator of opioid-dependent pathways.
• Impaired pain sensation in mice lacking prokineticin 2.
• Suppression of the p75 neurotrophin receptor in uninjured sensory neurons reduces neuropathic pain after nerve injury.
• Vesicular glutamate transporter VGLUT2 expression levels control quantal size and neuropathic pain.
• Interleukin-2: a potential treatment option for postherpetic neuralgia?
• Antihyperalgesic effects of loperamide in a model of rat neuropathic pain are mediated by peripheral delta-opioid receptors.
• Synthesis and biological evaluation of several structural analogs of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand.
• Intrathecal administration of Cav3.2 and Cav3.3 antisense oligonucleotide reverses tactile allodynia and thermal hyperalgesia in rats following chronic compression of dorsal root of ganglion.
• Intrathecally administered COX-2 but not COX-1 or COX-3 inhibitors attenuate streptozotocin-induced mechanical hyperalgesia in rats.
• Analgesic and anti-inflammatory dose-response relationship of 7.5 and 15 mg meloxicam after lower third molar removal: a double-blind, randomized, crossover study.
• Effects of (S)-3,4-DCPG, an mGlu8 receptor agonist, on inflammatory and neuropathic pain in mice.
• Dynorphin A activates bradykinin receptors to maintain neuropathic pain.
• The neural cell adhesion molecule antibody blocks cold water swim stress-induced analgesia and cell adhesion between lymphocytes and cultured dorsal root ganglion neurons.
• New evidence for the involvement of spinal fractalkine receptor in pain facilitation and spinal glial activation in rat model of monoarthritis.
• Protease-activated receptor 2 sensitizes the transient receptor potential vanilloid 4 ion channel to cause mechanical hyperalgesia in mice.
• 5-Heteroatom substituted pyrazoles as canine COX-2 inhibitors. Part III: molecular modeling studies on binding contribution of 1-(5-methylsulfonyl)pyrid-2-yl and 4-nitrile.
• Safety and efficacy of short-term celecoxib before elective percutaneous coronary intervention for stable angina pectoris.
• A study of AVINZA (morphine sulfate extended-release capsules) for chronic moderate-to-severe noncancer pain conducted under real-world treatment conditions--the ACCPT Study.
• Pregabalin in central neuropathic pain associated with spinal cord injury: a placebo-controlled trial.
• The leptin-deficient (ob/ob) mouse: a new animal model of peripheral neuropathy of type 2 diabetes and obesity.
• C-Peptide reverses nociceptive neuropathy in type 1 diabetes.
• SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice.
• P-glycoprotein ATPase activating effect of opioid analgesics and their P-glycoprotein-dependent antinociception in mice.
• Synthesis and SAR of novel 2-arylthiazolidinones as selective analgesic N-type calcium channel blockers.
• Na(V)1.7 mutant A863P in erythromelalgia: effects of altered activation and steady-state inactivation on excitability of nociceptive dorsal root ganglion neurons.
• Modulation of neuronal activity in CNS pain pathways following propofol administration in rats: Fos and EEG analysis.
• Injection of nuclear factor-kappa B decoy into the sciatic nerve suppresses mechanical allodynia and thermal hyperalgesia in a rat inflammatory pain model.
• Pentoxifylline attenuates the development of hyperalgesia in a rat model of neuropathic pain.
• GABAA but not GABAB receptors in the rostral anterior cingulate cortex selectively modulate pain-induced escape/avoidance behavior.
• Three-month efficacy and safety of acetaminophen extended-release for osteoarthritis pain of the hip or knee: a randomized, double-blind, placebo-controlled study.
• Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis.
• Differential and synergistic effects of selective norepinephrine and serotonin reuptake inhibitors in rodent models of pain.
• Neuropeptide Y modulates effects of bradykinin and prostaglandin E2 on trigeminal nociceptors via activation of the Y1 and Y2 receptors.
• Efficacy and safety of OPANA ER (oxymorphone extended release) for relief of moderate to severe chronic low back pain in opioid-experienced patients: a 12-week, randomized, double-blind, placebo-controlled study.
• Molecular basis of Ca(v)2.3 calcium channels in rat nociceptive neurons.
• Elucidation of the bioactive conformation of the N-substituted trans-3,4-dimethyl-4-(3-hydroxyphenyl)piperidine class of mu-opioid receptor antagonists.
• Synthesis and pharmacological evaluation of novel octahydro-1H-pyrido[1,2-a]pyrazine as mu-opioid receptor antagonists.
• 2-triazole-substituted adenosines: a new class of selective A3 adenosine receptor agonists, partial agonists, and antagonists.
• Diabetic neuropathy differs in type 1 and type 2 diabetes.
• Crystal structures of human adenosine kinase inhibitor complexes reveal two distinct binding modes.
• The non-psychoactive cannabis constituent cannabidiol is an orally effective therapeutic agent in rat chronic inflammatory and neuropathic pain.
• Lamotrigine for treatment of pain associated with diabetic neuropathy: results of two randomized, double-blind, placebo-controlled studies.
• Dual role of 5-HT3 receptors in a rat model of delayed stress-induced visceral hyperalgesia.
• Treatment with sumatriptan 50 mg in the mild phase of migraine attacks in patients with infrequent attacks: a randomised, double-blind, placebo-controlled study.
• Synthesis and evaluation of N-3 substituted phenoxypropyl piperidine benzimidazol-2-one analogues as NOP receptor agonists with analgesic and sedative properties.
• Thiazolidinedione class of peroxisome proliferator-activated receptor gamma agonists prevents neuronal damage, motor dysfunction, myelin loss, neuropathic pain, and inflammation after spinal cord injury in adult rats.
• A stomatin-domain protein essential for touch sensation in the mouse.
• An SCN9A channelopathy causes congenital inability to experience pain.
• Role of the CX3CR1/p38 MAPK pathway in spinal microglia for the development of neuropathic pain following nerve injury-induced cleavage of fractalkine.
• Intrathecal interleukin-10 gene therapy attenuates paclitaxel-induced mechanical allodynia and proinflammatory cytokine expression in dorsal root ganglia in rats.
• TRPV1+ sensory neurons control beta cell stress and islet inflammation in autoimmune diabetes.
• 1,5-Biaryl pyrrole derivatives as EP1 receptor antagonists. Structure-activity relationships of 6-substituted and 5,6-disubstituted benzoic acid derivatives.
• Spinal administration of a delta opioid receptor agonist attenuates hyperalgesia and allodynia in a rat model of neuropathic pain.
• Sodium channel blockade may contribute to the analgesic efficacy of antidepressants.
• Effectiveness and satisfaction with zolmitriptan 5 mg nasal spray for treatment of migraine in real-life practice: results of a postmarketing surveillance study.
• Tramadol in the treatment of neuropathic cancer pain: a double-blind, placebo-controlled study.
• The hypnotic, electroencephalographic, and antinociceptive properties of nonpeptide ORL1 receptor agonists after intravenous injection in rodents.
• An interdisciplinary expert consensus statement on assessment of pain in older persons.
• Protease-activated receptor-4: a novel mechanism of inflammatory pain modulation.
• Effects of corticoliberin CRF(4-6) fragment on pain sensitivity in rats.
• Arylpiperazinylalkylpyridazinones and analogues as potent and orally active antinociceptive agents: synthesis and studies on mechanism of action.
• Prospective randomized, double-blind, placebo-controlled study of pre- and postoperative administration of a COX-2-specific inhibitor as opioid-sparing analgesia in major colorectal surgery.
• Protective effects of bendazac lysine on diabetic peripheral neuropathy in streptozotocin-induced diabetic rats.
• Kv7.2-7.5 voltage-gated potassium channel (KCNQ2-5) opener, retigabine, reduces capsaicin-induced visceral pain in mice.
• Roles of capsaicin-sensitive primary afferents in differential rat models of inflammatory pain: a systematic comparative study in conscious rats.
• Endomorphin-1 analogs with enhanced metabolic stability and systemic analgesic activity: design, synthesis, and pharmacological characterization.
• Synthesis and pharmacological evaluation of some dual-acting amino-alcohol ester derivatives of flurbiprofen and 2-[1,1'-biphenyl-4-yl]acetic acid: a potential approach to reduce local gastrointestinal toxicity.
• Effect of CP55,940 on mechanosensory spinal neurons following chronic inflammation.
• Cyclin-dependent kinase 5 modulates nociceptive signaling through direct phosphorylation of transient receptor potential vanilloid 1.
• Sensitization of unmyelinated sensory fibers of the joint nerve to mechanical stimuli by interleukin-6 in the rat: an inflammatory mechanism of joint pain.
• Role of peripheral hyperpolarization-activated cyclic nucleotide-modulated channel pacemaker channels in acute and chronic pain models in the rat.
• Further characterization of a rat model of varicella zoster virus-associated pain: Relationship between mechanical hypersensitivity and anxiety-related behavior, and the influence of analgesic drugs.
• 4-amino-5-aryl-6-arylethynylpyrimidines: structure-activity relationships of non-nucleoside adenosine kinase inhibitors.
• Synthesis of novel curcumin analogues and their evaluation as selective cyclooxygenase-1 (COX-1) inhibitors.
• Interleukin-6 mediates low-threshold mechanical allodynia induced by intrathecal HIV-1 envelope glycoprotein gp120.
• Altered antinociceptive efficacy of tramadol over time in rats with painful peripheral neuropathy.
• Diclofenac epolamine is effective in the treatment of acute migraine attacks. A randomized, crossover, double blind, placebo-controlled, clinical study.
• A randomized, double-blind, one-week study comparing effects of a novel COX-2 inhibitor and naproxen on the gastric mucosa.
• Anti-allodynic efficacy of botulinum neurotoxin A in a model of neuropathic pain.
• Chiral tetrahydroquinoline derivatives as potent anti-hyperalgesic agents in animal models of sustained inflammation and chronic neuropathic pain.
• A single dose of liposome-encapsulated hydromorphone provides extended analgesia in a rat model of neuropathic pain.
• Thienorphine: receptor binding and behavioral effects in rhesus monkeys.
• Lacosamide in painful diabetic peripheral neuropathy: a phase 2 double-blind placebo-controlled study.
• Resistance to morphine analgesic tolerance in rats with deleted transient receptor potential vanilloid type 1-expressing sensory neurons.
• A comparison of the glutamate release inhibition and anti-allodynic effects of gabapentin, lamotrigine, and riluzole in a model of neuropathic pain.
• GISP: a novel brain-specific protein that promotes surface expression and function of GABA(B) receptors.
• Local administration of N-acetylaspartylglutamate (NAAG) peptidase inhibitors is analgesic in peripheral pain in rats.
• Gastrointestinal safety and anti-inflammatory effects of a hydrogen sulfide-releasing diclofenac derivative in the rat.
• Identification and characterization of 4-methylbenzyl 4-[(pyrimidin-2-ylamino)methyl]piperidine-1-carboxylate, an orally bioavailable, brain penetrant NR2B selective N-methyl-D-aspartate receptor antagonist.
• Evaluation of anticonvulsant and analgesic effects of benzyl- and benzhydryl ureides.
• A retrospective pooled analysis of duloxetine safety in 23,983 subjects.
• 5-HT acts on nociceptive primary afferents through an indirect mechanism to induce hyperalgesia in the subcutaneous tissue.
• Central glucocorticoid receptors regulate the upregulation of spinal cannabinoid-1 receptors after peripheral nerve injury in rats.
• Design, synthesis, and biological evaluation of substituted 2-alkylthio-1,5-diarylimidazoles as selective COX-2 inhibitors.
• Evaluation of the patient acceptable symptom state in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis.
• Structural modifications of (1S,3S)-3-amino-4-difluoromethylenecyclopentanecarboxylic acid, a potent irreversible inhibitor of GABA aminotransferase.
• Synthesis, pharmacological evaluation and electrochemical studies of novel 6-nitro-3,4-methylenedioxyphenyl-N-acylhydrazone derivatives: Discovery of LASSBio-881, a new ligand of cannabinoid receptors.
• Structurally novel histamine H3 receptor antagonists GSK207040 and GSK334429 improve scopolamine-induced memory impairment and capsaicin-induced secondary allodynia in rats.
• From pyrroles to 1-oxo-2,3,4,9-tetrahydro-1H-beta-carbolines: a new class of orally bioavailable mGluR1 antagonists.
• The coexistence of neuropathic pain, sleep, and psychiatric disorders: a novel treatment approach.
• Analgesic actions of N-arachidonoyl-serotonin, a fatty acid amide hydrolase inhibitor with antagonistic activity at vanilloid TRPV1 receptors.
• Antinociceptive efficacy of lacosamide in the monosodium iodoacetate rat model for osteoarthritis pain.
• Long-term safety and tolerability of oxcarbazepine in painful diabetic neuropathy.
• Synthesis and structure-activity relationships of N-substituted spiropiperidines as nociceptin receptor ligands.
• CXCR4 chemokine receptor signaling mediates pain hypersensitivity in association with antiretroviral toxic neuropathy.
• Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison.
• Tolerability to nabumetone and meloxicam in patients with nonsteroidal anti-inflammatory drug intolerance.
• Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial.
• Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.
• Early intervention with almotriptan: results of the AEGIS trial (AXERT Early Migraine Intervention Study).
• Comparison of the in vitro apparent permeability and stability of opioid mimetic compounds with that of the native peptide.
• Activation of the extracellular signal-regulated kinase in the amygdala modulates pain perception.
• The function neutralizing anti-TrkA antibody MNAC13 reduces inflammatory and neuropathic pain.
• Anti-nociceptive and anti-allodynic effects of a high affinity NOP hexapeptide [Ac-RY(3-Cl)YRWR-NH2] (Syn 1020) in rodents.
• Thromboembolic cardiovascular risk among arthritis patients using cyclooxygenase-2-selective inhibitor or nonselective cyclooxygenase inhibitor nonsteroidal anti-inflammatory drugs.
• MK-0703 (a cyclooxygenase-2 inhibitor) in acute pain associated with dental surgery: a randomized, double-blind, placebo- and active comparator-controlled dose-ranging study.
• Role for protease activity in visceral pain in irritable bowel syndrome.
• Gastrointestinal side effects of etoricoxib in patients with osteoarthritis: results of the Etoricoxib versus Diclofenac Sodium Gastrointestinal Tolerability and Effectiveness (EDGE) trial.
• Pharmacological evaluation of opioid and non-opioid analgesics in a murine bone cancer model of pain.
• Inhibition of tolerance to spinal morphine antinociception by low doses of opioid receptor antagonists.
• Novel malonamide derivatives as potent kappa opioid receptor agonists.
• Antinociceptive pharmacology of N-(4-chlorobenzyl)-N'-(4-hydroxy-3-iodo-5-methoxybenzyl) thiourea, a high-affinity competitive antagonist of the transient receptor potential vanilloid 1 receptor.
• Antinociceptive synergy between the cannabinoid receptor agonist WIN 55,212-2 and bupivacaine in the rat formalin test.
• A randomized, double-blind, placebo-controlled pilot study of IV morphine-6-glucuronide for postoperative pain relief after knee replacement surgery.
• Valdecoxib is as efficacious as diclofenac in the treatment of acute low back pain.
• Patient compliance with SSRIs and gabapentin in painful diabetic neuropathy.
• Pharmacological characterization of a selective COX-2 inhibitor MF-tricyclic, [3-(3,4-difluorophenyl)-4-(4-(methylsulfonyl)phenyl)-2-(5H)-furanone], in multiple preclinical species.
• Involvement of chloride channel coupled GABA(C) receptors in the peripheral antinociceptive effect induced by GABA(C) receptor agonist cis-4-aminocrotonic acid.
• Glyceryl trinitrate spray in the management of painful diabetic neuropathy: a randomized double blind placebo controlled cross-over study.
• The antinociceptive effect of 2-chloro-2'-C-methyl-N6-cyclopentyladenosine (2'-Me-CCPA), a highly selective adenosine A1 receptor agonist, in the rat.
• Novel 2-aminobenzothiazoles as selective neuronal nitric oxide synthase inhibitors.
• Calcitonin gene-related peptide analogues with aza and indolizidinone amino acid residues reveal conformational requirements for antagonist activity at the human calcitonin gene-related peptide 1 receptor.
• Comparison of the effects of diclofenac or other non-steroidal anti-inflammatory drugs (NSAIDs) and diclofenac or other NSAIDs in combination with proton pump inhibitors (PPI) on hospitalisation due to peptic ulcer disease.
• Ibuprofen sodium dihydrate, an ibuprofen formulation with improved absorption characteristics, provides faster and greater pain relief than ibuprofen acid.
• Characterization of the antinociceptive actions of bicifadine in models of acute, persistent, and chronic pain.
• Impact of disease characteristics on the efficacy of duloxetine in diabetic peripheral neuropathic pain.
• Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vivo studies.
• Pharmacological characterization of the nociceptin/orphanin FQ receptor antagonist SB-612111 [(-)-cis-1-methyl-7-[[4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol]: in vitro studies.
• NO-donor COX-2 inhibitors. New nitrooxy-substituted 1,5-diarylimidazoles endowed with COX-2 inhibitory and vasodilator properties.
• Randomized double-blind study comparing the efficacy and safety of lamotrigine and amitriptyline in painful diabetic neuropathy.
• Novel 1-oxyl-2-substitutedphenyl-4,4,5,5-tetramethylimidazolines: synthesis, selectively analgesic action, and QSAR analysis.
• Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma.
• Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials.
• A randomized, double-blind, placebo-controlled study of venlafaxine XR in out-patients with tension-type headache.
• Rapid modulation of micro-opioid receptor signaling in primary sensory neurons.
• Activation of transient receptor potential vanilloid type-1 channel prevents adipogenesis and obesity.
• The selective cyclooxygenase-2 inhibitor celecoxib reduces bone resorption, but not bone formation, in ovariectomized mice in vivo.
• Short-term efficacy of rofecoxib and diclofenac in acute shoulder pain: a placebo-controlled randomized trial.
• Risk of serious upper gastrointestinal events with concurrent use of NSAIDs and SSRIs: a case-control study in the general population.
• PLC-beta 3 signals upstream of PKC epsilon in acute and chronic inflammatory hyperalgesia.
• A critical role of toll-like receptor 2 in nerve injury-induced spinal cord glial cell activation and pain hypersensitivity.
• Enzymatic synthesis of capsaicin analogs and their effect on the T-type Ca2+ channels.
• Cardiovascular risk of cyclooxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs.
• Small interfering RNA-mediated selective knockdown of Na(V)1.8 tetrodotoxin-resistant sodium channel reverses mechanical allodynia in neuropathic rats.
• Genetic approaches identify differential roles for alpha4beta2* nicotinic receptors in acute models of antinociception in mice.
• Synthesis and biological evaluation of chiral alpha-aminoanilides with central antinociceptive activity.
• Continuous infusion of the cannabinoid WIN 55,212-2 to the site of a peripheral nerve injury reduces mechanical and cold hypersensitivity.
• 4-aryl-5-(4-piperidyl)-3-isoxazolol GABAA antagonists: synthesis, pharmacology, and structure-activity relationships.
• Evaluation of nitrate-substituted pseudocholine esters of aspirin as potential nitro-aspirins.
• Cell-specific alterations of T-type calcium current in painful diabetic neuropathy enhance excitability of sensory neurons.
• A randomized, double-blind, 8-week crossover study of once-daily controlled-release tramadol versus immediate-release tramadol taken as needed for chronic noncancer pain.
• Antinociceptive effects of the novel spirocyclopiperazinium salt compound LXM-10 in mice.
• Mice genetically deficient in neuromedin U receptor 2, but not neuromedin U receptor 1, have impaired nociceptive responses.
• Antiinflammatory and antinociceptive effects of the selective histamine H4-receptor antagonists JNJ7777120 and VUF6002 in a rat model of carrageenan-induced acute inflammation.
• Naloxone acts as a potent analgesic in transgenic mouse models of sickle cell anemia.
• Dose escalating safety study of CNS 5161 HCl, a new neuronal glutamate receptor antagonist (NMDA) for the treatment of neuropathic pain.
• Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat-mediated activation of the receptor.
• A 6-month, randomized, double-masked, placebo-controlled study evaluating the effects of the protein kinase C-beta inhibitor ruboxistaurin on skin microvascular blood flow and other measures of diabetic peripheral neuropathy.
• Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial.
• Antinociceptive efficacy of lacosamide in rat models for tumor- and chemotherapy-induced cancer pain.
• Involvement of cannabinoid (CB1)-receptors in the development and maintenance of opioid tolerance.
• 4-substituted indazoles as new inhibitors of neuronal nitric oxide synthase.
• Sumatriptan-naproxen for acute treatment of migraine: a randomized trial.
• Pharmacological properties of bivalent ligands containing butorphan linked to nalbuphine, naltrexone, and naloxone at mu, delta, and kappa opioid receptors.
• Potent nonpeptide antagonists of the bradykinin B1 receptor: structure-activity relationship studies with novel diaminochroman carboxamides.
• A role for G protein-coupled receptor kinase 2 in mechanical allodynia.
• Evaluation of the anti-inflammatory and anti-nociceptive activities of novel synthesized melatonin analogues.
• The effect of low-dose insulin on mechanical sensitivity and allodynia in type I diabetes neuropathy.
• The fatty acid amide hydrolase inhibitor URB597 (cyclohexylcarbamic acid 3'-carbamoylbiphenyl-3-yl ester) reduces neuropathic pain after oral administration in mice.
• Efficacy of noradrenergic and serotonergic antidepressants in chronic back pain: a preliminary concentration-controlled trial.
• Multicentre evaluation of the adenosine agonist GR79236X in patients with dental pain after third molar extraction.
• Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 2.
• The impact of neuropathic pain on health-related quality of life: review and implications.
• Finasteride, a 5alpha-reductase inhibitor, potentiates antinociceptive effects of morphine, prevents the development of morphine tolerance and attenuates abstinence behavior in the rat.
• Potent bradykinin B(1) receptor antagonists: 4-Substituted phenyl cyclohexanes.
• Synthesis and structure-activity relationships of 4-hydroxy-4-phenylpiperidines as nociceptin receptor ligands: Part 1.
• A molecular basis of analgesic tolerance to cannabinoids.
• Antibodies to nerve growth factor (NGF) reverse established tactile allodynia in rodent models of neuropathic pain without tolerance.
• Pharmacological, behavioural and mechanistic analysis of HIV-1 gp120 induced painful neuropathy.
• In-vitro investigation of oxazol and urea analogues of morphinan at opioid receptors.
• Synergistic antinociception by the cannabinoid receptor agonist anandamide and the PPAR-alpha receptor agonist GW7647.
• Pharmacological studies with a nonpeptidic, delta-opioid (-)-(1R,5R,9R)-5,9-dimethyl-2'-hydroxy-2-(6-hydroxyhexyl)-6,7-benzomorphan hydrochloride ((-)-NIH 11082).
• Role of spinal voltage-dependent calcium channel alpha 2 delta-1 subunit in the expression of a neuropathic pain-like state in mice.
• Gene transfer to interfere with TNFalpha signaling in neuropathic pain.
• Satisfaction with current migraine therapy: experience from 3 centers in US and Sweden.
• Botulinum toxin type a prophylactic treatment of episodic migraine: a randomized, double-blind, placebo-controlled exploratory study.
• Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial.
• Effect of pain intensity and time to administration on responsiveness to almotriptan: results from AXERT 12.5 mg Time Versus Intensity Migraine Study (AIMS).
• The efficacy, safety and carry-over effect of diacerein in the treatment of painful knee osteoarthritis: a randomised, double-blind, NSAID-controlled study.
• Antihyperalgesic and analgesic properties of the N-methyl-d-aspartate (NMDA) receptor antagonist neramexane in a human surrogate model of neurogenic hyperalgesia.
• Long-term use of controlled-release oxycodone for noncancer pain: results of a 3-year registry study.
• The chemokine CX3CL1/fractalkine interferes with the antinociceptive effect induced by opioid agonists in the periaqueductal grey of rats.
• AM404 decreases Fos-immunoreactivity in the spinal cord in a model of inflammatory pain.
• Novel inhibitors of fatty acid amide hydrolase.
• Constitutive GABA expression via a recombinant adeno-associated virus consistently attenuates neuropathic pain.
• A randomized, controlled, trial of controlled release paroxetine in fibromyalgia.
• Antinociceptive action of myricitrin: Involvement of the K(+) and Ca(2+) channels.
• Discovery and Characterization of 4'-(2-Furyl)-N-pyridin-3-yl-4,5'-bipyrimidin-2'-amine (LAS38096), a Potent, Selective, and Efficacious A(2B) Adenosine Receptor Antagonist.
• Loss-of-function mutations in the Nav1.7 gene underlie congenital indifference to pain in multiple human populations.
• Pharmacological, Pharmacokinetic, and Primate Analgesic Efficacy Profile of the Bradykinin B1 Receptor Antagonist ELN441958.
• Contribution of Ca(2+) -dependent protein kinase C in the spinal cord to the development of mechanical allodynia in diabetic mice.
• Discovery of 2-[(2,4-Dichlorophenyl)amino]-N-[(tetrahydro- 2H-pyran-4-yl)methyl]-4-(trifluoromethyl)- 5-pyrimidinecarboxamide, a Selective CB2 Receptor Agonist for the Treatment of Inflammatory Pain.
• Lumiracoxib 400 mg once daily is comparable to indomethacin 50 mg three times daily for the treatment of acute flares of gout.
• P2X(3) Receptor Mediates Heat Hyperalgesia in a Rat Model of Trigeminal Neuropathic Pain.
• Bradykinin B(1) antagonists: Biphenyl SAR studies in the cyclopropanecarboxamide series.
• Novel and potent 3-(2,3-dichlorophenyl)-4-(benzyl)-4H-1,2,4-triazole P2X(7) antagonists.
• A-803467, a potent and selective Nav1.8 sodium channel blocker, attenuates neuropathic and inflammatory pain in the rat.
• New Diagnosis of Hypertension Among Celecoxib and Nonselective NSAID Users: A Population-Based Cohort Study (June).
• Pregabalin in restless legs syndrome with and without neuropathic pain.
• CJ-023,423 (N-[({2-[4-(2-ethyl-4, 6-dimethyl-1H-imidazo [4, 5-c] pyridin-1-yl) phenyl] ethyl} amino) carbonyl]-4-methylbenzenesulfonamide), a novel, potent and selective prostaglandin EP4 receptor antagonist with antihyperalgesic properties.
• Interleukin-1ra inhibits Fos expression and hyperalgesia in rats.
• Bifunctional [2',6'-Dimethyl-l-tyrosine(1)]endomorphin-2 Analogues Substituted at Position 3 with Alkylated Phenylalanine Derivatives Yield Potent Mixed mu-Agonist/delta-Antagonist and Dual mu-Agonist/delta-Agonist Opioid Ligands.
• Discovery, Synthesis, and Structure Activity of a Highly Selective alpha7 Nicotinic Acetylcholine Receptor Antagonist.
• Involvement of Y(5) receptors in neuropeptide Y agonist-induced analgesic-like effect in the rat hot plate test.
• Synergy between Delta(9)-tetrahydrocannabinol and morphine in the arthritic rat.
• Cyclic benzamidines as orally efficacious NR2B-selective NMDA receptor antagonists.
• Activation of the 5-HT(1B/D) receptor reduces hindlimb neurogenic inflammation caused by sensory nerve stimulation and capsaicin.
• Protective effect of glucosamine against ibuprofen-induced peptic ulcer in rats.
• Use of gabapentin for perioperative pain control -- A meta-analysis.
• alpha-Methylation at benzylic fragment of N-aryl-N'-benzyl ureas provides TRPV1 antagonists with better pharmacokinetic properties and higher efficacy in inflammatory pain model.
• Biaryl cannabinoid mimetics-Synthesis and structure-activity relationship.
• Phase 1A Safety Assessment of Intravenous Amitriptyline.
• alpha(1)-Adrenergic Receptors Augment P2X(3) Receptor-Mediated Nociceptive Responses in the Uninjured State.
• Curative-like analgesia in a neuropathic pain model: Parametric analysis of the dose and the duration of treatment with a high-efficacy 5-HT(1A) receptor agonist.
• Riluzole, a glutamate release inhibitor, induces loss of righting reflex, antinociception, and immobility in response to noxious stimulation in mice.
• The Pharmacokinetics of the Conopeptide Contulakin-G (CGX-1160) After Intrathecal Administration: An Analysis of Data from Studies in Beagles.
• Liposome-encapsulated ropivacaine for topical anesthesia of human oral mucosa.
• Experimental neuropathy in mice is associated with delayed behavioral changes related to anxiety and depression.
• Design and synthesis of some new thiazolo [3,2-b]-1,2,4-triazole-5(6H)-ones substituted with flurbiprofen as anti-inflammatory and analgesic agents.
• Design, Synthesis, and Biological Evaluation of Novel Bifunctional C-Terminal-Modified Peptides for delta/mu Opioid Receptor Agonists and Neurokinin-1 Receptor Antagonists.
• Evaluation of NR2B peptide as subunit vaccines against experimental neuropathic pain.
• Antinociceptive effect and interaction of uncompetitive and competitive NMDA receptor antagonists upon capsaicin and paw pressure testing in normal and monoarthritic rats.
• In vitro and in vivo study of poly(ethylene glycol) conjugated ketoprofen to extend the duration of action.
• Bivalent ligand approach on 4-[2-(3-methoxyphenyl)ethyl]-1-(2-methoxyphenyl)piperazine: Synthesis and binding affinities for 5-HT(7) and 5-HT(1A) receptors.
• Efficacy and safety evaluation of once-daily OROS hydromorphone in patients with chronic low back pain: a pilot open-label study (DO-127).
• Iontophoretic transdermal system using fentanyl compared with patient-controlled intravenous analgesia using morphine for postoperative pain management.
• Clinical Experience with Transdermal and Orally Administered Opioids in Palliative Care Patients--A Retrospective Study.
• Transmucosal fentanyl vs intravenous morphine in doses proportional to basal opioid regimen for episodic-breakthrough pain.
• The Application of 3D-QSAR Studies for Novel Cannabinoid Ligands Substituted at the C1' Position of the Alkyl Side Chain on the Structural Requirements for Binding to Cannabinoid Receptors CB1 and CB2.
• Differential expression of the capsaicin receptor TRPV1 and related novel receptors TRPV3, TRPV4 and TRPM8 in normal human tissues and changes in traumatic and diabetic neuropathy.
• The impact of the opioids fentanyl and morphine on nociception and bone destruction in a murine model of bone cancer pain.
• 2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 1: Discovery of CB(2) receptor selective compounds.
• Antihyperalgesic Effect of a Recombinant Herpes Virus Encoding Antisense for Calcitonin Gene-related Peptide.
• Oral Gabapentin Activates Spinal Cholinergic Circuits to Reduce Hypersensitivity after Peripheral Nerve Injury and Interacts Synergistically with Oral Donepezil.
• BDNF contributes to animal model neuropathic pain after peripheral nerve transection.
• Amelioration of pain and histopathologic joint abnormalities in the Col1-IL-1beta(XAT) mouse model of arthritis by intraarticular induction of mu-opioid receptor into the temporomandibular joint.
• 2-Arylimino-5,6-dihydro-4H-1,3-thiazines as a new class of cannabinoid receptor agonists. Part 2: Orally bioavailable compounds.
• In vitro and in vivo studies on UFP-112, a novel potent and long lasting agonist selective for the nociceptin/orphanin FQ receptor.
• Tramadol and several anticonvulsants synergize in attenuating nerve injury-induced allodynia.
• Mice lacking central serotonergic neurons show enhanced inflammatory pain and an impaired analgesic response to antidepressant drugs.
• Efficacy of lisinopril in migraine prophylaxis--an open label study.
• Efficacy of duloxetine on cognition, depression, and pain in elderly patients with major depressive disorder: an 8-week, double-blind, placebo-controlled trial.
• Antihyperalgesic effects of vanilloid-1 and bradykinin-1 receptor antagonists following spinal cord injury in rats.
• Pyridazinoquinolinetriones as NMDA Glycine-Site Antagonists with Oral Antinociceptive Activity in a Model of Neuropathic Pain.
• Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients.
• Botulinum toxin type-a in the prevention of migraine: a double-blind controlled trial.
• 4-Amino-5-vinyl-3(2H)-pyridazinones and analogues as potent antinociceptive agents: Synthesis, SARs, and preliminary studies on the mechanism of action.
• The antinociceptive effect of systemic gabapentin is related to the type of sensitization-induced hyperalgesia.
• Agmatine induces anti-hyperalgesic effects in diabetic rats and a superadditive interaction with D-CPP, a NMDA-receptor antagonist.
• Comparison of the mGluR1 antagonist A-841720 in rat models of pain and cognition.
• Effect of S-diclofenac, a novel hydrogen sulfide releasing derivative, on carrageenan-induced hindpaw oedema formation in the rat.
• A role for transcriptional repressor Methyl-CpG-binding protein 2 and plasticity-related gene serum- and glucocorticoid-inducible kinase 1 in the induction of inflammatory pain states.
• Pre-emptive antinociceptive effects of a synthetic cannabinoid in a model of neuropathic pain.
• Peripheral kinin B(1) and B(2) receptor-operated mechanisms are implicated in neuropathic nociception induced by spinal nerve ligation in rats.
• The rat vanilloid receptor splice variant VR.5'sv blocks TRPV1 activation.
• Cannabinoids mediate analgesia largely via peripheral type 1 cannabinoid receptors in nociceptors.
• The effect of the palmitoylethanolamide analogue, palmitoylallylamide (L-29) on pain behaviour in rodent models of neuropathy.
• The neurocytokine, interleukin-6, corrects nerve dysfunction in experimental diabetes.
• Design, synthesis, binding, and molecular modeling studies of new potent ligands of cannabinoid receptors.
• N-(6,7-Dichloro-2,3-dioxo-1,2,3,4-tetrahydroquinoxalin-5-yl)-N-alkylsulfonamides as peripherally restricted N-methyl-d-aspartate receptor antagonists for the treatment of pain.
• Suppression by intrathecal BmK IT2 on rat spontaneous pain behaviors and spinal c-Fos expression induced by formalin.
• Effects of ropivacaine on pain after laparoscopic cholecystectomy: a prospective, randomized study.
• Sensory neuron sodium channel Nav1.8 is essential for pain at low temperatures.
• A Comparison of the Efficacy and Safety of Celecoxib 200 mg and Celecoxib 400 mg Once Daily in Treating the Signs and Symptoms of Psoriatic Arthritis.
• The synthetic cannabinoids attenuate allodynia and hyperalgesia in a rat model of trigeminal neuropathic pain.
• Anti-hypernociceptive properties of agmatine in persistent inflammatory and neuropathic models of pain in mice.
• Pharmacological validation of a model of cystitis pain in the mouse.
• A randomized, double-blind, celecoxib- and placebo-controlled study of the effectiveness of CS-706 in acute postoperative dental pain.
• Effect of CJ-42794, A Selective Antagonist of Prostaglandin E Receptor Subtype 4, on Ulcerogenic and Healing Responses in Rat Gastrointestinal Mucosa.
• Synthesis and cannabinoid activity of 1-substituted-indole-3-oxadiazole derivatives: Novel agonists for the CB(1) receptor.
• In Vitro Structure-Activity Relationship and In Vivo Characterization of 1-(Aryl)-3-(4-(amino)benzyl)urea Transient Receptor Potential Vanilloid 1 Antagonists.
• Levels of neuropeptides nocistatin, nociceptin/orphanin FQ and their precursor protein in a rat neuropathic pain model.
• Structure-Activity Studies and Analgesic Efficacy of N-(3-Pyridinyl)-Bridged Bicyclic Diamines, Exceptionally Potent Agonists at Nicotinic Acetylcholine Receptors.
• Novel Vanilloid Receptor-1 Antagonists: 1. Conformationally Restricted Analogues of trans-Cinnamides.
• Novel Vanilloid Receptor-1 Antagonists: 2. Structure-Activity Relationships of 4-Oxopyrimidines Leading to the Selection of a Clinical Candidate.
• Novel Vanilloid Receptor-1 Antagonists: 3. The Identification of a Second-Generation Clinical Candidate with Improved Physicochemical and Pharmacokinetic Properties.
• PHARMACOLOGICAL CHARACTERIZATION OF THE MUSCARINIC AGONIST, WAY-132983, IN IN VITRO AND IN VIVO MODELS OF CHRONIC PAIN.
• Efficacy of duloxetine in the treatment of generalized anxiety disorder in patients with clinically significant pain symptoms.
• Modified behavioral characteristics following ablation of the voltage-dependent calcium channel beta3 subunit.
• Discovery of a novel class of benzazepinone Na(v)1.7 blockers: Potential treatments for neuropathic pain.
• Effects of nimesulide on pain and on synovial fluid concentrations of substance P, interleukin-6 and interleukin-8 in patients with knee osteoarthritis: comparison with celecoxib.
• Rational design of 7-arylquinolines as non-competitive metabotropic glutamate receptor subtype 5 antagonists.
• Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats.
• Comparative Pharmacological Profiles of Morphine and Oxycodone under a Neuropathic Pain-Like State in Mice: Evidence for Less Sensitivity to Morphine.
• Antinociceptive profile of a selective metabotropic glutamate receptor 1 antagonist YM-230888 in chronic pain rodent models.
• Effects of Loperamide on Mechanical Allodynia Induced by Herpes Simplex Virus Type-1 in Mice.
• Decreased sensitivity to thermal pain in rats bred for high anxiety-related behaviour is attenuated by citalopram or diazepam treatment.
• The effects of pharmacological blockade of the 5-HT(6) receptor on formalin-evoked nociceptive behaviour, locomotor activity and hypothalamo-pituitary-adrenal axis activity in rats.
• The transient receptor potential vanilloid 1 (TRPV1) receptor protects against the onset of sepsis after endotoxin.
• Botulinum toxin type A for migraine prophylaxis in the Japanese population: an open-label prospective trial.
• Sch35966 is a potent, selective agonist at the peripheral cannabinoid receptor (CB(2)) in rodents and primates.
• Oxcarbazepine for treating paroxysmal painful symptoms in multiple sclerosis: a pilot study.
• Spinal NKCC1 blockade inhibits TRPV1-dependent referred allodynia.
• The synthetic cannabinoid HU-210 attenuates neural damage in diabetic mice and hyperglycemic pheochromocytoma PC12 cells.
• Gabapentin and An Opioid Combination Versus Opioid Alone for the Management of Neuropathic Cancer Pain: A Randomized Open Trial.
• In vitro pharmacological characterization of novel isoxazolopyridone derivatives as allosteric metabotropic glutamate receptor 7 (mGluR7) antagonists.
• The Ca(v)2.3 calcium channel antagonist SNX-482 reduces dorsal horn neuronal responses in a rat model of chronic neuropathic pain.
• The CRF(1) receptor antagonist, R121919, attenuates the severity of precipitated morphine withdrawal.
• Caprolactams as potent CGRP receptor antagonists for the treatment of migraine.
• Fatty acyl amides of endogenous tetrahydroisoquinolines are active at the recombinant human TRPV1 receptor.
• Codeine/acetaminophen and hydrocodone/acetaminophen combination tablets for the management of chronic cancer pain in adults: A 23-day, prospective, double-blind, randomized, parallel-group study.
• Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study.
• The kinin B(1) receptor antagonist SSR240612 reverses tactile and cold allodynia in an experimental rat model of insulin resistance.
• Involvement of EphB1 receptor/EphrinB2 ligand in neuropathic pain.
• The effect of an endogenous compound 1-methyl-1,2,3,4,-tetrahydroisoquinoline on morphine-induced analgesia, dependence and neurochemical changes in dopamine metabolism in rat brain structures.
• Postoperative Administration of the Analgesic Tramadol, but Not the Selective Cyclooxygenase-2 Inhibitor Parecoxib, Abolishes Postoperative Hyperalgesia in a New Model of Postoperative Pain in Rats.
• Design, synthesis, and biological evaluation of tricyclic heterocycle-tetraamine conjugates as potent NMDA channel blockers.
• DP-155, a Lecithin Derivative of Indomethacin, is a Novel Nonsteroidal Antiinflammatory Drug for Analgesia and Alzheimer's Disease Therapy.
• Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, multicentre study.
• Activation of phosphatidylinositol 3-kinase and protein kinase B/Akt in dorsal root ganglia and spinal cord contributes to the neuropathic pain induced by spinal nerve ligation in rats.
• 4-Amino-5-substituted-3(2H)-pyridazinones as Orally Active Antinociceptive Agents: Synthesis and Studies on the Mechanism of Action.
• alpha-Substituted N-(4-tert-butylbenzyl)-N'-[4-(methylsulfonylamino)benzyl]thiourea analogues as potent and stereospecific TRPV1 antagonists.
• Naphthalen-1-yl-(4-pentyloxynaphthalen-1-yl)methanone: A Potent, Orally Bioavailable Human CB(1)/CB(2) Dual Agonist with Antihyperalgesic Properties and Restricted Central Nervous System Penetration.
• Effect of Risk Factors on Complicated and Uncomplicated Ulcers in the TARGET Lumiracoxib Outcomes Study.
• A randomized placebo-controlled trial comparing the efficacy of etoricoxib 30mg and ibuprofen 2400mg for the treatment of patients with osteoarthritis.
• A randomized, double-blind, placebo-controlled study evaluating twice daily dosing of pregabalin for relief of neuropathic pain associated with diabetic peripheral neuropathy.
• Comparative efficacy and tolerability of two sustained-release formulations of diclofenac: results of a double-blind, randomised study in patients with osteoarthritis and a reappraisal of diclofenacs use in this patient population.
• Frequency of low back pain among men and women aged 30 to 64 years in France. Results of two national surveys.
• Delay of cutaneous wound closure by morphine via local blockade of peripheral tachykinin release.
• A tarantula peptide against pain via ASIC1a channels and opioid mechanisms.
• 5-HT3 receptor antagonists regulate autonomic cardiac dysfunction in primary fibromyalgia syndrome.
• Efficacy and tolerability of naratriptan for short-term prevention of menstrually related migraine: data from two randomized, double-blind, placebo-controlled studies.
• The discovery of potent, selective, and orally bioavailable hNK(1) antagonists derived from pyrrolidine.
• A Multicentre, Randomised, Double-Blind Study Comparing the Efficacy and Tolerability of Intramuscular Dexketoprofen versus Diclofenac in the Symptomatic Treatment of Acute Low Back Pain.
• Effects of a Monoclonal Antibody Raised Against Nerve Growth Factor on Skeletal Pain and Bone Healing Following Fracture of the C57BL/6J Mouse Femur.
• Subcutaneous, intrathecal and periaqueductal grey administration of asimadoline and ICI-204448 reduces tactile allodynia in the rat.
• Sulfonamide derivatives as new potent and selective CB(2) cannabinoid receptor agonists.
• Intravenous paracetamol as adjunctive treatment for postoperative pain after cardiac surgery: a double blind randomized controlled trial.
• The anti-allergic drug, N-(3',4'-dimethoxycinnamonyl) anthranilic acid, exhibits potent anti-inflammatory and analgesic properties in arthritis.
• A double-blind, crossover assessment of the sedative and analgesic effects of intranasal dexmedetomidine.
• Structure-Activity Relationship Study on N-(1,2,3,4-Tetrahydronaphthalen-1-yl)-4-aryl-1-piperazinehexanamides, a Class of 5-HT(7) Receptor Agents. 2.
• The local antinociceptive effects of paracetamol in neuropathic pain are mediated by cannabinoid receptors.
• Analysis of the antinociceptive effect of systemic administration of tramadol and dexmedetomidine combination on rat models of acute and neuropathic pain.
• Nanostructured lipid carrier (NLC) based gel of celecoxib.
• Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade.
• Unique spirocyclopiperazinium salt. Part 4: Modification of dispirocyclopiperazinium (DSPZ) salts as analgesics.
• (-)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (Tapentadol HCl): a Novel {micro} Opioid Receptor Agonist / Norepinephrine Reuptake Inhibitor with Broad Spectrum Analgesic Properties.
• Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-l-carnitine.
• The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans.
• 3-Hydroxy-4-methoxyindolomorphinans as delta opioid selective ligands.
• Double-Blind, Placebo-Controlled Trial of Lamotrigine in Combination with Other Medications for Neuropathic Pain.
• An Open-Label, Multi-Dose Efficacy and Safety Study of Intramuscular Tetrodotoxin in Patients with Severe Cancer-Related Pain.
• Effect of peripheral endothelin-1 concentration on carcinoma-induced pain in mice.
• Effects of the bisphosphonate ibandronate on hyperalgesia, substance P, and cytokine levels in a rat model of persistent inflammatory pain.
• The selective and non-selective cyclooxygenase inhibitors valdecoxib and piroxicam induce the same postoperative analgesia and control of trismus and swelling after lower third molar removal.
• Comparison of pre- versus post-incision administration of intraplantar indomethacin and MK886 in a rat model of postoperative pain.
• Design, Synthesis, and In Vitro Evaluation of Carbamate Derivatives of 2-Benzoxazolyl- and 2-Benzothiazolyl-(3-hydroxyphenyl)-methanones as Novel Fatty Acid Amide Hydrolase Inhibitors.
• Pharmacokinetic and pharmacodynamic evaluations of novel oral morphine sustained release granules.
• Systemic Lidocaine Shortens Length of Hospital Stay After Colorectal Surgery: A Double-blinded, Randomized, Placebo-controlled Trial.
• WIN 55,212-2 prevents mechanical allodynia but not alterations in feeding behaviour induced by chronic cisplatin in the rat.
• Structure-Activity Relationship Studies of Spinorphin as a Potent and Selective Human P2X(3) Receptor Antagonist.
• Efficacy and tolerability of oxymorphone immediate release for acute postoperative pain after abdominal surgery: a randomized, double-blind, active- and placebo-controlled, parallel-group trial.
• Efficacy and tolerability of valdecoxib in treating the signs and symptoms of severe rheumatoid arthritis: a 12-week, multicenter, randomized, double-blind, placebo-controlled study.
• Antihyperalgesic effects induced by the IL-1 receptor antagonist anakinra and increased IL-1beta levels in inflamed and osteosarcoma-bearing mice.
• Delta-Opioid Receptors Are Critical for Tricyclic Antidepressant Treatment of Neuropathic Allodynia.
• Influence of tiagabine on the antinociceptive action of morphine, metamizole and indomethacin in mice.
• Peripheral inflammatory hyperalgesia modulates morphine delivery to the brain: a role for P-glycoprotein.
• Gabapentin action and interaction on the antinociceptive effect of morphine on visceral pain in mice.
• Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials.
• Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: a 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial.